Multiple Myeloma Treatment at John Theurer Cancer Center
Multiple myeloma, a cancer of the bone marrow, is becoming increasingly common as the population ages. The John Theurer Cancer Center has one of the largest myeloma programs in the world, offering a dedicated team of specialists for all stages of multiple myeloma. Patients seek us out for our personalized care and access to advanced treatment options not available elsewhere.Diagnosing Your Exact Type of Multiple Myeloma
At John Theurer Cancer Center, our doctors are leaders in multiple myeloma research, having published the first complete genomic portrait of this cancer. Our approach begins with specialized imaging, along with molecular and genetic analysis, to provide the most accurate diagnosis possible. This precision medicine approach allows us to tailor treatments specifically to your cancer, offering the best chance for success.
Treatment Options
You will have access to the latest medical therapies for multiple myeloma, including medications developed through our research, such as thalidomide, lenalidomide, pomalidomide, bortezomib, carfilzomib, elotuzumab, daratumumab, and more.
John Theurer Cancer Center is one of the few centers worldwide offering CAR T-cell therapy for multiple myeloma. This breakthrough immunotherapy uses your own immune cells to target and destroy cancer cells. Patients who had relapsed after prior treatments have achieved long-term remission through CAR T-cell therapy. Learn more about CAR T-Cell therapy.
Our team has pioneered the use of advanced immunotherapy for multiple myeloma, including T-cell engagers, antibody-drug conjugates, and checkpoint inhibitors. These therapies activate your immune system to find and eliminate cancer cells.
If you have been diagnosed with smoldering multiple myeloma or MGUS (monoclonal gammopathy of undetermined significance), we offer personalized surveillance to monitor your condition. Our team will guide you on whether treatment is necessary and provide access to clinical trials focused on early detection and optimal treatment timing.
At John Theurer Cancer Center, we have one of the largest blood and marrow stem cell programs in the country, performing over 250 transplants annually for multiple myeloma. Our center specializes in autologous and allogeneic stem cell transplants, with a focus on reducing complications and lowering the risk of cancer recurrence. We are global leaders in combining checkpoint inhibitors with stem cell transplantation, providing patients with the most advanced care available. Our Blood and Marrow Stem Cell Transplant Program.
Our Research and Clinical Trials
At Hackensack Meridian Health, we are committed to research that enhances the safety and effectiveness of stem cell transplants. Our clinical trials focus on reducing transplant complications and minimizing disease recurrence. We are the first in the world to combine checkpoint inhibitors with stem cell transplants, ensuring that the immune system is empowered to eliminate any remaining cancer cells post-treatment.
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose ...
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell ...
- Selinexor and Backbone Treatments of Multiple Myeloma Patients
